---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-254807"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2022-09-30T23:59:59+00:00"
generated_at: "2026-06-23T06:24:52.706909+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences acquires AavantiBio in stock deal, raises $75M PIPE, appoints new CEO

## Summary
- Acquires AavantiBio for 15% of SLDB common stock plus $1,000; AavantiBio lead program in Friedreich's Ataxia gene therapy.
- Concurrent $75M PIPE at $0.47/share; PIPE shares equal ~159.6M shares, closing after merger.
- Current CEO Ilan Ganot resigns effective closing; Alexander (Bo) Cumbo (AavantiBio CEO) to become new CEO; Adam Koppel joins board.
- Support agreements: 79% of AavantiBio and 29.8% of SLDB stockholders commit to vote in favor.
- Closing conditions include Nasdaq listing approval and stockholder approvals; termination fee $310k.

## SEC filing metadata
- accession: 0001193125-22-254807
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2022-09-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312522254807/0001193125-22-254807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312522254807/d375823d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-254807
- JSON: https://secwatch.observer/filing/0001193125-22-254807.json
- Plain text: https://secwatch.observer/filing/0001193125-22-254807.txt

## Key facts
- Executive change
  Erin Powers Brennan resigned as Chief Legal Officer and Secretary at Solid Biosciences Inc..
  - Action: resigned
  - Role: Chief Legal Officer and Secretary
  source text: On September 29, 2022, Erin Powers Brennan also notified the Company of her intention to resign as the Company’s Chief Legal Officer and Secretary, subject to, and contingent and effective upon, the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312522254807/0001193125-22-254807-index.htm
- Executive change
  Alexander Cumbo was appointed as President and Chief Executive Officer at Solid Biosciences Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On September 29, 2022, the Company entered into an employment agreement with Alexander Cumbo (the “Cumbo Employment Agreement”), pursuant to which Mr. Cumbo will serve as the Company’s President and Chief Executive Officer, subject to his appointment to such position by the Board and subject to, and contingent and effective upon, the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312522254807/0001193125-22-254807-index.htm
- Executive change
  Ilan Ganot resigned as Chief Executive Officer and President at Solid Biosciences Inc..
  - Action: resigned
  - Role: Chief Executive Officer and President
  source text: On September 29, 2022, Ilan Ganot notified the Company of his intention to resign as the Company’s Chief Executive Officer and President, subject to, and contingent and effective upon, the closing of the Merger (such date, the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312522254807/0001193125-22-254807-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.